Dose: 7.143 to 14.286 mg/kg
Single Dose: 11 (10.7145)
Frequency: 12 hourly
Route: PO
Instructions: As Required

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Glymidine also known as Glycodiazine. . It is of Synthetic origin and belongs to Pyrimidine. It belongs to Potassium Channel (ATP sensitive) antagonist pharmacological group on the basis of mechanism of action and also classified in Antidiabetic Agent, Sulfonylurea pharmacological group.The Molecular Weight of Glymidine is 331.30. Its pKa is 5.7.

Glymidine is contraindicated in conditions like Renal failure,Iddm,Ketosis,Hepatic failure.

The severe or irreversible adverse effects of Glymidine, which give rise to further complications include Hypoglycemia.Glymidine produces potentially life-threatening effects which include Hypoglycemia, Hypoglycemia, Hypoglycemia. which are responsible for the discontinuation of Glymidine therapy.The signs and symptoms that are produced after the acute overdosage of Glymidine include Hypoglycemia.The symptomatic adverse reactions produced by Glymidine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Weakness, Dizziness, Fatigue, Skin rashes, Pruritus, Epigastric discomfort, GI upset, Dryness of mouth, Arthralgia, Backache, Pancytopenia, Changes in LFT, Skin rashes, dizziness.

Glymidine is primarily indicated in conditions like Maturity onset diabetes, Non-insulin dependent diabetes mellitus.

No data regarding the interactions of Glymidine was found.

Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab Protect from Moisture.